Boehringer Ingelheim (BI) launches an unbranded version of its adalimumab biosimilar; Alvotech and Kashiv Biosciences partner for an omalizumab biosimilar candidate; the FDA issues a complete response letter (CRL) for Biocon’s insulin aspart biosimilar.
Boehringer Ingelheim (BI) launches an unbranded version of its adalimumab biosimilar; Alvotech and Kashiv Biosciences partner for an omalizumab biosimilar candidate; the FDA issues a complete response letter (CRL) for Biocon’s insulin aspart biosimilar.
BI’s Unbranded Adalimumab Biosimilar
BI launched an unbranded version of its adalimumab biosimilar (Cyltezo) at an 81% discount to the originator (Humira). For comparison, the company’s branded version of the drug is priced 5% lower than Humira, which currently has a list price of $6922 per month.
Branded Cyltezo launched on the US market in July 2023, and was approved as the first interchangeable adalimumab biosimilar (second interchangeable biosimilar overall) in November 2021.
The dual-pricing strategy has been very popular in the adalimumab biosimilar space, where 3 other adalimumab biosimilars (Amjevita, Hyrimoz, Hulio) launched with 2 wholesale acquisition costs (WACs). According to Julie Reed, MS, executive director of the Biosimilars Forum, this is to ensure that companies can convince pharmacy benefit managers to put their products on formulary (high WAC) and to ensure that uninsured patients can have access to the product at a decent price (low WAC).
The news comes as the FDA approved an interchangeability designation for Abrilada.
Alvotech, Kashiv Biosciences Partnership
Alvotech and Kashiv Biosciences have signed an exclusive licensing agreement for AVT23 (ADL018), a proposed omalizumab referencing Xolair, which is currently in clinical development.
“We are delighted to partner commercial rights to our omalizumab biosimilar program to Alvotech, a global biosimilar company, for multiple major geographies…. We look forward to continued enrollment of patients in our global phase 3 clinical study to expand access to this treatment for patients,” said Sandeep Gupta, PhD, CEO of Kashiv.
The partnership covers all 27 EU member stakes, the United Kingdom, Australia, Canada, and New Zealand. Per the agreement’s terms, Alvotech will have exclusive license to commercialize AVT23 and Kashiv Biosciences will manufacture and develop the biosimilar. Kashiv will also receive upfront payments and subsequent milestone payments and royalties.
Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E to treat allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.
“We are very pleased to enter into this exclusive development and commercialization agreement for omalizumab. This demonstrates how Alvotech can leverage its platform and pursue attractive markets either by developing and manufacturing products in house or through in-licensing. Here, we can deploy Alvotech’s market access expertise as well as leverage our global commercial partnerships,” said Robert Wessman, chairman and CEO of Alvotech.
CRL for Biocon’s Insulin Aspart Biosimilar
The FDA has issued a CRL for Biocon Biologic’s insulin aspart biosimilar candidate, according to a report from BQ Prime. For reference, there are no insulin aspart biosimilars in the United States and there are 3 in the European Union, including Kirsty, which was developed by Biocon Biologics.
The CRL did not cite any issues with the submitted data package or the biosimilar product itself; instead, it referenced deficiencies with the pre-approval manufacturing facility inspection of Biocon’s Malaysian facility that was held in August 2022.
Biocon submitted a Corrective and Preventive Action plan in September 2022 that the FDA deemed adequate. The plan would require a re-inspection of the facility. A spokesperson from Biocon indicated that the company will continue to engage with the FDA to resolve the issues.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.